AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS · Delayed Price · Currency is USD
0.0094
+0.0009 (10.59%)
Nov 4, 2025, 3:11 PM EST
AXIM Biotechnologies Revenue
AXIM Biotechnologies had revenue of $17.48K in the quarter ending June 30, 2024, with 76.04% growth. This brings the company's revenue in the last twelve months to $92.90K, up 257.95% year-over-year. In the year 2023, AXIM Biotechnologies had annual revenue of $39.52K with 345.27% growth.
Revenue (ttm)
92.90K
Revenue Growth
+257.95%
P/S Ratio
32.54
Revenue / Employee
13.27K
Employees
7
Market Cap
3.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 39.52K | 30.64K | 345.27% |
| Dec 31, 2022 | 8.88K | -51.59K | -85.32% |
| Dec 31, 2021 | 60.46K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
AXIM Biotechnologies News
- 1 year ago - VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 - GlobeNewsWire
- 1 year ago - AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease - Business Wire
- 2 years ago - AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test - Business Wire
- 2 years ago - Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 2 years ago - AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch - GlobeNewsWire